Here, we will introduce the virus and its pathogenic mechanism in detail. At the same time, you will learn how to obtain functional anti-virus antibodies and peptides through our technology platform.

In this episode, we will study the overview of membrane protein and membrane protein antibody.

What is de novo antibody sequencing? What are the steps of de novo antibody sequencing?  Are there any challenges in de novo antibody sequencing? How do we overcome these difficulties in antibody sequence analysis? Creative Biolabs will describe all these issues in the episode.

This episode introduces the De Novo Antibody Sequencing service provided by Creative Biolabs, which can distinguish leucine from isoleucine with 100% accuracy. This valuable breakthrough improves functional analysis and verification and cost-effectively builds a strong foundation for downstream applications.

In this episode, we will introduce the definition and background of immunogenicity and importance of immunogenicity therapeutic biologics development.

In this episode, Creative Biolabs will introduce technologies of monoclonal antibody development, including hybridoma, surface display, B cell immortalization, and transgenetic technology. You will have a whole concept of mAb development after listening to the episode.

As a new preparation technology for genetically engineered antibodies, antibody library technology has important theoretical and practical values in the cloning of human antibodies, antibody performance modification, and antibody gene research. Here, we will explore the de novo antibody library screening technologies and corresponding applications.

What is antibody humanization? How to humanize an antibody? The definition and humanization process are illustrated by Creative Biolabs in this episode.

In the episode, Creative Biolabs will detailed the mechanism of antibody diversity—gene rearrangement and antibody sequencing service. We hope this episode can help you understand the principle of complicated antibody diversity.

Here, we discussed the important features of antitumor antibodies, with a focus on how such antibodies promote immune effector mechanisms to control tumor growth. Approved and in clinical phase therapeutic antibodies are also mentioned.